Patrick Burnett, MD, PhD, Chief Medical Officer of Arcutis Biotherapeutics, reviews new data on the use of topical roflumilast (Zoryve) in scalp and body psoriasis, seborrheic dermatitis, and atopic dermatitis in patients with diverse skin types presented at the 2024 Fall Clinical Dermatology Conference in Las Vegas, NV. Dr. Burnett also discusses the ongoing topical renaissance in inflammatory skin diseases.
